Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
On January 13, 2022, the board of directors of H-Cyte, Inc. (the “Company”) appointed Richard Rosenblum and Matthew Anderer as new directors of the Company, effective January 17, 2022.
Mr. Rosenblum (62) is a business veteran and entrepreneur in the areas of the financial services, capital markets, healthcare, technology and real estate. His experience ranges from serving as managing director at several investment merchant banks to heading companies as a C-suite executive. He also sits on the boards of public and private healthcare, life sciences and technology-sector companies.
Mr. Rosenblum is currently President, CFO and Board Member of Innovative Payment Solutions, Inc., a California-based FinTech company focused on building a 21st century universal digital payment and money remittance platform. As the founder of Harborview Capital Advisors, LLC, Mr. Rosenblum leads a team of strategic advisors in the areas of capital formation, merchant banking and management consulting, and has raised more than $250 million in capital funding for companies. Since founding it over 20 years ago, Mr. Rosenblum has served as manager and director of Harborview Property Management LLC, raising over $100 million while managing domestic and international commercial and multi-family real estate assets. From 2008 to 2014, Mr. Rosenblum was Director, President and Executive Chairman of Alliqua Biomedical Inc. (NASDAQ: ALQA), a leader in hydrogel manufacturing technology in the wound care sector.
Mr. Rosenblum received his B.A. in Finance & Accounting from the State University of New York at Buffalo in 1981, graduating summa cum laude.
Mr. Rosenblum will receive $5,000 a month as compensation from the Company for his service as a director.
Mr. Anderer (55) started his career in the United States Air Force as a fast jet and special operations pilot and instructor before taking operational and staff officer roles with Special Operations Command and NATO. He has commanded worldwide airlift capability of the highest posts within the White House and from a technology perspective, he has directed a range of high-profile, high-value acquisition projects. Mr. Anderer was the Director of the US Air Force leadership and citizenship development program for 220,000 cadets before taking command of the busiest air mobility group in the world, responsible for support to destinations world-wide. Among other contingency crisis operations in this capacity, Matt played a crucial role establishing robust, resilient, and repeatable processes to prevent the potential spread of the Ebola Virus for aircraft, cargo and passengers that transited sub-Saharan West Africa. He is currently the training systems Country Integration Lead for Lockheed Martin’s F-35 International customers, a position that he has held since prior to 2017.
Most recently, Mr. Anderer was also a member of the Board for Deverra Theraputics, a clinical stage cell therapy company headquartered in Seattle. He is a graduate of Villanova University, Air Command and Staff College, Naval Staff College and the Geneva Center for Security Policy.
Mr. Anderer will receive $5,000 a month as compensation from the Company for his service as a director.
The board of directors of the Company has affirmatively determined that both Mr. Rosenblum and Mr. Anderer meet the applicable standards for independent directors under Rule 10A-3 of the Securities Exchange Act of 1934.
There is no arrangement or understanding between either Mr. Rosenblum or Mr. Anderer and any other persons pursuant to which either Mr. Rosenblum or Mr. Anderer was elected as a director of the Company. There are no family relationships between either Mr. Rosenblum or Mr. Anderer and any of the Company’s officers or directors. Other than as described herein, there are no other transactions to which the Company or any of its subsidiaries is a party in which either Mr. Rosenblum or Mr. Anderer has a material interest subject to disclosure under Item 404(a) of Regulation S-K.
HCYT~~H-CYTE Combines Clinical Outcomes and Scientific Development to Launch New Centers for Respiratory Health Press Release | 09/08/2021 CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company dedicated to developing and delivering new treatments for patients with chronic respiratory and pulmonary disorders, today announced the launch of its newly-named ‘Centers for Respiratory Health’.
Effective immediately, the Company’s “Lung Health Institute” facilities will begin operating under the new name. The change is evolutionary and represents a commitment to data-driven, real-world evidence, along with the need to more accurately capture the broadening scope of the work the H-CYTE clinical development team and its medical professionals accomplish at its Centers.
H-CYTE Chief Executive Officer Robert Greif stated, “We have a new management team, new scientific developments, new supportive shareholders, and clinically relevant, real world data. The name ‘Centers for Respiratory Health’ represents the company’s strategic intent to provide the highest quality, patient-centric, evidence-driven care possible.” Greif added, “Our adjunctive therapy for patients who are already maximizing their maintenance medications for lung disorders, has the potential to drive improvement in lung health for our patients. This next generation therapy brings a new option for patients, pulmonologists and healthcare providers where few choices exist today."
Dr. Tanya Rhodes, Chief Technology Officer for H-CYTE, stated, “We are very excited about the name change to ‘Centers for Respiratory Health’ as it reflects our ongoing commitment to demonstrate the science behind our technology and the positive clinical outcomes we are observing. The field of regenerative medicine is moving at a very fast pace, and our goal is to be at the forefront, providing quality evidence-based care to the patients we serve.”
H-CYTE recently announced the results and publication of two, real world, observational studies supporting the efficacy of its innovative autologous treatment in improving lung health. Both studies resulted in statistically significant improvement(s) in pulmonary function at 3 months after just one treatment.* These improvements were seen out to 12 months in the Longitudinal Assessment of FEV1 Change Following Autologous Cellular Therapy study. Additionally, statistically significant Quality of Life improvements at 3, 6 and 12 months were reported in both studies. Based on these outcomes, the Company is currently planning a multi-center randomized, double-blind, head-to-head comparison trial involving H-CYTE’s innovative PRP-PBMC therapy, to be conducted by independent pulmonologists across the US.
H-CYTE has a nationwide network of Centers for Respiratory Health. Its mission is to deliver regionally-based, patient-focused, scientifically-backed respiratory care for those with lung disorders.
To learn more about the Centers for Respiratory Health and PRP-PBMC therapy, please visit www.CentersforRespiratoryHealth.com.
*Each patient is different, and results may vary. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to suggest diagnosis, treatment, cure, or prevention of any disease.
About H-CYTE, Inc.
H-CYTE is a medical biosciences company focused in the field of regenerative medicine. H-CYTE’s mission is to become a leader in next-generation, cellular therapeutics for the treatment of chronic health conditions, with the ultimate goal of improving patient lives. For more information about H-CYTE, please visit www.HCYTE.com.
Safe Harbor Statement
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While H-CYTE believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those outlined in H-CYTE’s filings with the SEC, including but not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. H-CYTE expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
CONTACTS
H-CYTE Investor Relations Jason Assad Jassad@HCYTE.com 678-570-6791
H CYTE : Combines Clinical Outcomes and Scientific Development to Launch New Centers for Respiratory Health 09/08/2021 | 08:01am EDT share with twitter share with LinkedIn share with facebook CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company dedicated to developing and delivering new treatments for patients with chronic respiratory and pulmonary disorders, today announced the launch of its newly-named ‘Centers for Respiratory Health’.
Effective immediately, the Company’s “Lung Health Institute” facilities will begin operating under the new name. The change is evolutionary and represents a commitment to data-driven, real-world evidence, along with the need to more accurately capture the broadening scope of the work the H-CYTE clinical development team and its medical professionals accomplish at its Centers.
H-CYTE Chief Executive Officer Robert Greif stated, “We have a new management team, new scientific developments, new supportive shareholders, and clinically relevant, real world data. The name ‘Centers for Respiratory Health’ represents the company’s strategic intent to provide the highest quality, patient-centric, evidence-driven care possible.” Greif added, “Our adjunctive therapy for patients who are already maximizing their maintenance medications for lung disorders, has the potential to drive improvement in lung health for our patients. This next generation therapy brings a new option for patients, pulmonologists and healthcare providers where few choices exist today."
Dr. Tanya Rhodes, Chief Technology Officer for H-CYTE, stated, “We are very excited about the name change to ‘Centers for Respiratory Health’ as it reflects our ongoing commitment to demonstrate the science behind our technology and the positive clinical outcomes we are observing. The field of regenerative medicine is moving at a very fast pace, and our goal is to be at the forefront, providing quality evidence-based care to the patients we serve.”
H-CYTE recently announced the results and publication of two, real world, observational studies supporting the efficacy of its innovative autologous treatment in improving lung health. Both studies resulted in statistically significant improvement(s) in pulmonary function at 3 months after just one treatment.* These improvements were seen out to 12 months in the Longitudinal Assessment of FEV1 Change Following Autologous Cellular Therapy study. Additionally, statistically significant Quality of Life improvements at 3, 6 and 12 months were reported in both studies. Based on these outcomes, the Company is currently planning a multi-center randomized, double-blind, head-to-head comparison trial involving H-CYTE’s innovative PRP-PBMC therapy, to be conducted by independent pulmonologists across the US.
H-CYTE has a nationwide network of Centers for Respiratory Health. Its mission is to deliver regionally-based, patient-focused, scientifically-backed respiratory care for those with lung disorders.
To learn more about the Centers for Respiratory Health and PRP-PBMC therapy, please visit www.CentersforRespiratoryHealth.com.
*Each patient is different, and results may vary. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to suggest diagnosis, treatment, cure, or prevention of any disease.
About H-CYTE, Inc.
H-CYTE is a medical biosciences company focused in the field of regenerative medicine. H-CYTE’s mission is to become a leader in next-generation, cellular therapeutics for the treatment of chronic health conditions, with the ultimate goal of improving patient lives. For more information about H-CYTE, please visit www.HCYTE.com.
Safe Harbor Statement
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While H-CYTE believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those outlined in H-CYTE’s filings with the SEC, including but not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. H-CYTE expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
CONTACTS
H-CYTE Investor Relations Jason Assad Jassad@HCYTE.com 678-570-6791
Primary Logo Source: H-CYTE, Inc. 2021 GlobeNewswire, Inc., source Press Releases
Another one of your horrible calls. I think you are losing you touch a little. I guess most have learned and are now selling into your pumps. JMO. Lol.
These are in the top several Google results for "Lung Health Institute." It seems very possible that Wagner being in the stock will make it pump more in the future but I don't want to hold it since I think the company is a scam. GLTA
To clarify, Wagner is the majority controlling owner (60%) through FWHC BRIDGE, LLC which he is the sole manager of. So I think as long as he holds $8m in this and retains majority ownership, maybe he is not going to let the shareholders get too badly screwed over the medium to long term.
Stock reached .99 cents back in February with much less volume. 7 cents is just over 100% where it was yesterday. With this float and it being an OTCQB stock this is truly a gift. That’s why I grabbed mid 6s and 7s at the end. Any news, any updates this shoots up like nothing. You could see it how it moves how thin this is. Profit taking and old bag holders from the .99 cents top wanted out which is why it didn’t get the natural bounce
I’m all in for a bounce tomorrow but I don’t see it going back to 0.03 cents so I’m holding until they decide to pop it again! Learn how to play the OTC, not many floats like this, secure them when you see them
That LACK of Control Groups --- e.g., Placebo Group, Standard of Care, etc. --- is ESPECIALLY worrisome, to say the least. And I'm glad that YOU made note of that. THANK YOU!
Will go dead --- NO question about it. Tomorrow morning, just 30-minutes BEFORE the Market Open, toss HCYT into (for example) Etrade to get a looming PRICE on this stock. Etrade will display the "Extended Hours" price, which likely will be RED (down). Most iHub 'Pundits' would say that such is irrelevant --- but it is NOT.
The market cap is only 10 million right now. So it doesn't need to be a cure to have further upside IMO. As for the benefits or lack thereof from the treatment, I don't know how to ferret that out from the study they did. It's not great that it lacked a control group, but on the other hand, it was stated that COPD would normally be progressively degenerative and improvement was observed instead of degeneration, so that may mean that simply a lack of the pulmonary function worsening is already a substantive benefit. I'm not a medical expert so I don't know, just saying what seems plausible from my uneducated vantage point.
With ending up 150%, do you believe that this is likely to bounce or have continuation, or do you think it's more likely to go dead for months until another PR may happen months away?
"Are they just making that up?" Very possible. But, as I have already noted, TODAY's news is NOT impressive at all. READ the ultimate RESULTS of their COPD study. FAR-FAR-FAR from a medical 'CURE' for COPD --- NOR any substantive benefits at all. (IMO)
Note holders may have converted today. I would imagine the float is larger today than it was yesterday but not by a lot. Some dilution would account for the massive volume. End of the day, it held at a 150% gain. Not too bad, really.
This ran to .99 on 510,000 volume in February. It seems impossible that on over 18 million volume the top was 0.30 and it won't bounce at all.
Maybe I'm a fool but I doubled down around .07 so I have a cost average of .114 now.
Also as far as I can tell, it didn't even have PR for the February run.
If this is the first in a sequence of PRs then the run should keep going. I readily admit this is an ugly upthrust on the daily chart though.
It doesn't make any sense to me that this was just crushed like this on such high volume. But the upthrust in February is even worse, it pumped to .99 and closed at .14 on February 11th.
On January 21st was the last communication to shareholders before today's PR, and they claimed they are pursuing FDA application and other catalysts for which they received investment from the billionaire Todd Wagner:
Maybe I'm a sucker but I don't understand how the run is already dead. If this was a scam company how could they have gotten Todd Wagner to invest in it? Are they just making that up?
Anyone that bought this after 10:35 A.M. (NY), lost their proverbial SHIRT --- pure suckers' bate, AFTER that moment in time. But CONGRATS to 'EZ' dude, who likely made circa 4-times his play --- at least several thousand bucks!!! I ADMIRE that Chap!!!!
News 
Market Data 
Discover 
